Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. (PTGX) Stock Overview
Explore Protagonist Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
6.3B
P/E Ratio
-48.19
EPS (TTM)
$-2.05
ROE
-0.20%
PTGX Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Protagonist Therapeutics, Inc. (PTGX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 62.31, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $103.55.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -48.19 and a market capitalization of 6.3B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.